Characteristics and Response to Crizotinib in Lung Cancer Patients with MET Amplification Detected by Next-Generation Sequencing

Mesenchymal-epithelial transition (MET) is a proto-oncogene located on chromosome 7q21-31 that encodes a transmembrane tyrosine kinase receptor for hepatocyte growth factor (HGF) [1,2]. In lung cancer, mechanisms of MET pathway activation include MET overexpression and genetic alteration such as MET mutation or amplification [3]. A previous study reported that in epidermal growth factor receptor (EGFR) mutant lung adenocarcinoma samples, MET amplification was found in 21% of patients with acquired resistance to EGFR- tyrosine kinase inhibitors (TKI) and 3% of untreated patients [4].

Source: Lung Cancer - September 4, 2020 Category: Cancer & Oncology Authors: Jingwen Li, Yue Wang, Bo Zhang, Jianlin Xu, Shuhui Cao, Hua Zhong Source Type: research